Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares, rose in value, with the stock price down by -3.02% to the previous day’s close as strong demand from buyers drove the stock to $0.20.
Actively observing the price movement in the recent trading, the stock is buoying the session at $0.21, falling within a range of $0.196 and $0.2053. The value of beta (5-year monthly) is 1.592. Referring to stock’s 52-week performance, its high was $7.96, and the low was $0.18. On the whole, SYRS has fluctuated by -1.24% over the past month.
With the market capitalization of Syros Pharmaceuticals Inc currently standing at about $5.34 million, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SYRS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of SYRS currently trading nearly -10.27% and -49.46% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.82, while the 7-day volatility ratio is showing 12.19% which for the 30-day chart, stands at 14.97%. Furthermore, Syros Pharmaceuticals Inc (SYRS)’s beta value is 1.30, and its average true range (ATR) is 0.04.
A comparison of Syros Pharmaceuticals Inc (SYRS) with its peers suggests the former has fared considerably weaker in the market. SYRS showed an intraday change of -3.02% in today’s session so far, and over the past year, it shrunk by -97.09%%.
Data on historical trading for Syros Pharmaceuticals Inc (NASDAQ:SYRS) indicates that the trading volumes over the past 10 days have averaged 1.73 and over the past 3 months, they’ve averaged 9.75 million. According to company’s latest data on outstanding shares, there are 26.83 million shares outstanding.
Nearly 35.03% of Syros Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 36.34% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.1 million shares as on 2024-12-31, resulting in a short ratio of 0.37. According to the data, the short interest in Syros Pharmaceuticals Inc (SYRS) stood at 446.00 of shares outstanding as of 2024-12-31; the number of short shares registered in 2024-11-29 reached 2.23 million. The stock has fallen by -13.27% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SYRS stock heading into the next quarter.
